Antibodies to platelet-activating factor are associated with borderline hypertension, early atherosclerosis and the metabolic syndrome

Journal of Internal Medicine

Volumn 246, Issue 4, 1999, Pages 389-397

  Wu, R ^a   Lemne, C ^b   De Faire, U ^a   Frostegård, Johan ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies; Atherosclerosis; Hypertension; Metabolic syndrome; Platelet activating factor

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; THROMBOCYTE ACTIVATING FACTOR;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTERY WALL; ARTICLE; ATHEROGENESIS; B SCAN; BORDERLINE HYPERTENSION; CAROTID ARTERY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL;

ADULT; ANTIBODIES; ANTIBODY SPECIFICITY; ARTERIOSCLEROSIS; BLOOD PRESSURE; ENDOTHELIN-1; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; LIPOPROTEINS; MALE; MIDDLE AGED; PLATELET ACTIVATING FACTOR;

EID: 0006417042     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00570.x     Document Type: Article

References (49)

1. 1 Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s. Nature 1993; 362: 801-9.
2. 2 De Meyer GR, Herman AG. Vascular endothelial dysfunction. Prog Cardiovasc Dis 1997; 39: 325-42.
3. 3 Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arterioscler 1986; 6: 131-8.
4. 4 Frostegård J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low-density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990; 87: 904-8.
5. 5 Frostegård J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T cell activation by oxidized low density lipoprotein. Arterioscler Thromb 1992; 12: 461-7.
6. 6 Huang YH, Rönnelid J, Frostegård J. Oxidized LDL induces enhanced antibody formation and MHC class II-dependent IFN-gamma production in lymphocytes from healthy individuals. Arterioscler Thromb Vasc Biol 1995; 15: 1577-83.
7. 7 Frostegård J, Huang YH, Rönnelid J, Schäfer-Elinder L. PAF and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol 1997; 17: 963-8.
8. 8 Xu Q, Oberhuber G, Gruschwitz M, Wick G. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992; 12: 789-99.
9. 9 Xu Q, Willeit J, Marosi M et al. Association of serum antibodies to heat shock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255-9.
10. 10 Frostegård J, Kjellman B, Gidlund M, Jindal S, Kiessling R. Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atheroscler 1996; 121; 93-103.
11. 11 Halme S, Syrjälä H, Bloigu A et al. Lymphocyte responses to chlamydia antigens in patients with coronary heart disease. Eur Heart J 1997; 18: 1095-101.
12. 12 Salonen JT, Yla-Herttuala S, Yamamoto R et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7.
13. 13 Dzielak DJ. The immune system and hypertension. Hypertension 1992; 19: 136-44.
14. 14 Fu ML. Do immune system changes have a role in hypertension? J Hypertension 1995; 13: 1259-65.
15. 15 Tokumura A. A family of phospholipid autacoids: occurrence, metabolism and bioactions. Prog Lipid Res 1995; 34: 151-84.
16. 16 Bussolino F, Camussi G. Platelet-activating factor produced by endothelial cells. A molecule with autocrine and paracrine properties. Eur J Biochem 1995; 229: 327-37.
17. 17 McManus LM, Woodard DS, Deavers SI, Pinckard RN. PAF molecular heterogeneity: pathobiological implications. Lab Invest 1993; 69: 639-50.
18. 18 Korth R, Zimmermann K, Richter WO. Lipoprotein-associated paf (LA-paf) was found in washed human platelets and monocyte/macrophage-like U937 cells. Chem Phys Lipids 1994; 70: 109-16.
19. 19 Evangelou AM. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins, Leukotrienes Essential Fatty Acids 1994; 50: 1-28.
20. 20 Barquinero J, Ordi-Ros J, Selva A, Perez-Peman P, Vilardell M, Khamashta M. Antibodies against platelet-activating factor in patients with antiphospholipid antibodies. Lupus 1994; 3: 55-8.
21. 21 Lemne C, Jogestrand T, de Faire U. Carotid intima-media thickness and plaque in borderline hypertension. Stroke 1995; 26: 34-9.
22. 22 Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1986; 68: 215-22.
23. 23 Carlson K. Lipoprotein fractionation. J Clin Pathol 1973; 5 (Suppl. 26): 32-27.
24. 24 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
25. 25 Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993; 137; 959-65.
26. 26 Pavoa G, Roovete A, Hall K. Cross reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol 1991; 124: 620-29.
27. 27 Lemne C, Lundeberg T, Theodorsson E, de Faire U. Increased basal concentrations of plasma endothelin in borderline hypertension. J Hypertens 1994; 12: 1069-74.
28. 28 Lemne C, Lindvall K, Georglades A, Fredriksson M, de Faire U. Structural cardiac changes in relation to 24 hour ambulatory blood pressure levels in borderline hypertension. J Int Med 1995; 238: 49-57.
29. 29 Lemne C, Jogestrand T, de Faire U. Non-invasive assessment of vessel-wall change in hypertensives and normotensive controls. Clin Physiol 1992; 12: 497-502.
30. 30 Lemne C, Hamsten A, Karpe F, Nilsson-Ehle P, de Faire U. Dyslipoproteinemic changes in borderline hypertension. Hypertension 1994; 24: 605-10.
31. 31 Frostegård J, Lemne C, Andersson B, Kiessling R, de Faire U. Association of serum antibodies to heat shock protein 65 with borderline hypertension. Hypertension 1997; 29; 40-44.
32. 32 Frostegård J, Wu R, Haegerstrand C, Lemne C, de Faire U. Antibodies to endothelial cells in borderline hypertension. Circulation 1998; 98: 1092-8.
33. 33 Shimizu T, Mutoh H, Kato S. Platelet-activating factor receptor. Gene structure and tissue-specific regulation. Adv Exp Med Biol 1996; 416: 79-84.
34. 34 McNeil HP, Simpson RJ, Chesterman CN, Krilis CN. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci 1990; 87: 4120-24.
35. 35 Amiral J, Larrivaz I, Cluzeau D, Adam M. Standardization of immunoassays for antophospholipid antibodies with beta-2GP1 and role of other phospholipid cofactors. Haemostasis 1994; 24: 191-203.
36. 36 Najmey SS, Keil LB, Adib DY, DeBari VA. The association of antibodies to beta 2 glycoprotein 1 with the antiphospholipid syndrome; a meta-analysis. Ann Clin Lab Sci 1997; 27: 41-6.
37. 37 Hörkkö S, Miller E, Branch DW, Palinski W, Witztum J. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and ß2 glycoprotein 1 (and other proteins). Proc Natl Acad Sci 1997; 94: 10356-61.
38. 38 Huang YH, Schäfer-Elinder L, Owman H, Lorentzen JC, Rönnelid J, Frostegård J. Induction of IL-4 by platelet activating factor. Clin Exp Immunol 1996; 106: 143-8.
39. 39 Bonavida B, Mencia-Huerta JM, Braquet P. Effect of platelet-activating factor (PAF) on monocyte activation and production of tumor necrosis factor. Int Arch Allergy Appl Immunol 1989; 88: 157-60.
40. 40 Poubelle PE, Gingras D, Demers C, Dubois C, Harbour D, Grassi J. Platelet-activating factor (PAF-acether) enhances the concomitant production of TNF-α and IL-1 by subsets of human monocytes. Immunol 1991; 72: 181-7.
41. 41 Tjoelker LW, Wilder C, Eberhardt C et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374: 549-53.
42. 42 MacMahon SW, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-9.
43. 43 Hollander W, Prusty S, Kemper T, Rosene DL, Moss MB. The effects of hypertesion on cerebral atherosclerosis in the synomolgus monkey. Stroke 1993; 24: 1218-26.
44. 44 Sawchuk AP, Unthank JL, Davis TE, Dalsing MC. A prospective, in vivo study of the relationship between blood flow demodynamics and atherosclerosis in a hyperlipidemic swine model. J Vasc Surg 1994; 19: 58-63.
45. 45 Solberg LA, Strong JP. Risk factors and atherosclerotic lesions: a review of autopsy studies. Arteriosclerosis 1983; 3: 187-98.
46. 46 Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995; 96: 2322-30.
47. 47 Watson AD, Navab M, Hama SY et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95: 774-82.
48. 48 Wu R, de Faire U, Lemne C, Witztum J, Frostegård J. Serum antibodies to oxidized LDL are decreased in borderline hypertension. Hypertension 1999; 33: 53-9.
49. 49 Uyemura K, Demer LL, Castle SC et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-38.